Title | Evidence for dispensability of protein kinase R in host control of tuberculosis. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Mundhra S, Bryk R, Hawryluk N, Zhang T, Jiang X, Nathan C |
Journal | Eur J Immunol |
Volume | 48 |
Issue | 4 |
Pagination | 612-620 |
Date Published | 2018 04 |
ISSN | 1521-4141 |
Keywords | Animals, Cells, Cultured, eIF-2 Kinase, Female, Interferon-gamma, Interleukin-10, Macrophage Activation, Macrophages, Mice, Mice, Inbred C57BL, Mice, Knockout, Mycobacterium tuberculosis, Reactive Nitrogen Species, Tuberculosis, Tumor Necrosis Factor-alpha |
Abstract | Genetic deficiency of protein kinase R (PKR) in mice was reported to enhance macrophage activation in vitro in response to interferon-γ (IFNγ) and to reduce the burden of Mycobacterium tuberculosis (Mtb) in vivo (Wu et al. PloS One. 2012 7:e30512). Consistent with this, treatment of wild-type (WT) macrophages in vitro with a novel PKR inhibitor (Bryk et al., Bioorg. Med. Chem. Lett. 2011 21:4108-4114) also enhanced IFN-γ-dependent macrophage activation (Wu et al. PloS One. 2012 7:e30512). Here we show that co-treatment with IFN-γ and a new PKR inhibitor identified herein to be highly but not completely selective likewise induced macrophages to produce more reactive nitrogen intermediates (RNI) and tumor necrosis factor alpha (TNF-α) and less interleukin 10 (IL-10) than seen with IFN-γ alone. Unexpectedly, however, this new PKR inhibitor had a comparable effect on PKR-deficient macrophages. Retrospective investigation revealed that the PKR-deficient mice in (Wu et al. PloS One. 2012 7:e30512) had not been backcrossed. On comparing genetically matched PKR-deficient and WT mice, we saw no impact of PKR deficiency on macrophage activation in vitro or during the course of Mtb infection in vivo. In addition, although 129S1/SvImJ macrophage responses to IFN-γ were greater than those of C57BL/6J macrophages, PKR was not required to mediate the IFN-γ-dependent production of IL-10, RNI or TNF-α in either strain. Together the data cast doubt on PKR as a potential therapeutic target for tuberculosis. |
DOI | 10.1002/eji.201747180 |
Alternate Journal | Eur. J. Immunol. |
PubMed ID | 29436711 |
PubMed Central ID | PMC6361384 |
Grant List | R21 AI105807 / AI / NIAID NIH HHS / United States R33 AI105807 / AI / NIAID NIH HHS / United States |
Submitted by oks4001 on January 24, 2020 - 1:56pm